Compare Amphastar Pharmaceuticals Inc (AMPH) vs Anheuser-Busch Inbev SA (BUD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Anheuser-Busch Inbev SA — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.38 (market cap $826.08M), while Anheuser-Busch Inbev SA trades at $79.9 (market cap $153.32B). The key difference: Anheuser-Busch Inbev SA is far larger — about 185.6× Amphastar Pharmaceuticals Inc's market cap, and Anheuser-Busch Inbev SA pays a 1.69% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | BUD | |
|---|---|---|
Market Cap | $826.08M | $153.32B |
Sector | Health | Consumer Staples |
52-Week High | $30.81 | $85.09 |
52-Week Low | $16.87 | $57.10 |
Enterprise Value | $1.22B | $214.50B |
Dividend Yield | — | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% on the day, with a bearish technical signal from moving averages. Recent earnings missed estimates in Q1 2026, with revenue of $171.2 million and adjusted EPS of $0.42 versus $0.70 expected. The company is shifting focus toward proprietary drugs and biosimilars for growth, as noted at recent investor conferences.
Outlook is mixed: valuation ratios appear reasonable with P/E of 11.29 and EV/EBITDA of 6.32, but earnings misses and a Zacks Strong Sell rating highlight near-term risks. The consensus price target of $20.40 suggests modest upside if execution improves, though legal scrutiny and competitive pressures remain concerns.
BUD trades at $79.33, down 0.35% on the day, with a bearish technical signal despite recent earnings beats. The company shows solid fundamentals with a net income margin of 11.9% and positive cash flow trends, supported by a $1.17 dividend. Revenue remains stable near $59 billion, while debt-to-asset ratios have improved to 33.89% in 2025. Analyst consensus is bullish with a $90.08 price target, but technical indicators highlight near-term resistance at $80.
The outlook for BUD is cautiously optimistic, driven by premiumization strategies and digital expansion, though investor sentiment is tempered by bearish technical signals and industry-wide volume pressures. Key risks include changing consumer preferences and macroeconomic headwinds, but strong institutional support and consistent dividend payments provide a buffer for long-term holders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Anheuser-Busch Inbev SA
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.
Read more on BUD →
